Top Banner
Understanding SVT and Atrial Fibrillation Ramin Davoudi MD Medical Director Cardiac Arrhythmia Service
34

Understanding SVT and Atrial Fibrillation · 2016. 11. 4. · Understanding SVT and Atrial Fibrillation Ramin Davoudi MD Medical Director Cardiac Arrhythmia Service. Disclosures ...

Feb 07, 2021

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
  • Understanding SVT and Atrial Fibrillation

    Ramin Davoudi MD

    Medical Director

    Cardiac Arrhythmia Service

  • Disclosures

    • Speaker’s Bureau: Boston Scientific, Biotronik, Boerhinger-Ingelheim

    • Research: Biotronik, Boston Scientific, St Jude Medical

    • Corporate Investments: None

  • Objectives

    • Understand pathophysiology of SVT

    • Identify different SVT’s

    • Understand treatment options of a fib

    3

  • Mechanisms of SVT

    • Automaticity

    • Triggered Activity

    • Re-entry

    4

  • 5

  • Types of SVT

    • AV nodal reentrant tachycardia (70%)

    • AV reentrant tachycardia (20%)

    • Atrial tachycardia (9%)

    • Junctional tachycardia (1%)

    • Atrial Flutter

    • Atrial Fibrillation

  • SVT: Long RP vs Short RP

  • AVNRT

  • AVNRT

  • AVRT

  • Atrial Flutter

    • Typical

    • Counterclockwise/clockwise

    • Atypical

  • Atrial Flutter

  • 13

  • 14

  • Atrial Fibrillation

  • 16

  • 17

  • 18

  • 19

  • 20

  • Fire and ICE

    21

    Kuck et al. NEJM 2016

  • 22Kuck et al. NEJM 2016

  • 23 Roy et al NEJM 2000

  • 24 Pappone et al. JACC 2003

  • 25

    Wyse et al. NEJM 2002

    AFFIRM STUDY

  • 26

  • 27

  • Treatment

    • Beta blockers

    • Calcium Channel blockers

    • Antiarrhythmic Medications

    • Atrial fibrillation – Amiodarone, Sotalol, Dofetilide, Flecainide, Propafenone

    • AVRT – Flecainide, Propafenone, Amiodarone

  • Amiodarone

    • Most potent

    • CHF safe

    • Torsades

    • Liver metabolism

    • Extracardiac

    • Skin

    • Pulmonary

    • Thyroid

    • Lung

    • Nervous system

    • GI

    29

  • Sotalol

    • Kidney

    • Little Drug - Drug interaction

    • Not very potent

    • Torsades

    • ? CHF safe

    30

  • Tikosyn

    • Kidney

    • Drug interactions - Verapamil, Bactrim, HCTZ

    • Slightly more potent than sotalol

    • Torsades

    • CHF safe

    31

  • Flecainide/Propafenone

    • Not CHF safe

    • Liver/kidney

    • Drug interactions

    • Not many side effects (metallic taste, tremor, headache)

    • Rare Torsades - mostly conduction issues

    32

  • Conclusions

    • SVT mechanisms are few

    • Drugs are moderately effective

    • Treating SVT is becoming increasingly catheter based

    33

  • QUESTIONS?

    34